NYSE:NVS - Novartis Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$76.29 +0.12 (+0.16 %)
(As of 05/25/2018 12:31 PM ET)
Previous Close$76.67
Today's Range$76.12 - $76.82
52-Week Range$75.73 - $94.19
Volume24,861 shs
Average Volume1.42 million shs
Market Capitalization$177.12 billion
P/E Ratio15.89
Dividend Yield2.50%
Beta0.76

About Novartis (NYSE:NVS)

Novartis logoNovartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

Receive NVS News and Ratings via Email

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVS
CUSIPN/A
Phone41-61-324-1111

Debt

Debt-to-Equity Ratio0.33
Current Ratio1.17
Quick Ratio0.91

Price-To-Earnings

Trailing P/E Ratio15.89
Forward P/E Ratio14.50
P/E Growth1.66

Sales & Book Value

Annual Sales$49.11 billion
Price / Sales3.60
Cash Flow$7.6366 per share
Price / Cash9.99
Book Value$30.73 per share
Price / Book2.48

Profitability

EPS (Most Recent Fiscal Year)$4.81
Net Income$7.70 billion
Net Margins16.04%
Return on Equity16.23%
Return on Assets8.69%

Miscellaneous

Employees121,597
Outstanding Shares2,317,460,000

Novartis (NYSE:NVS) Frequently Asked Questions

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

How will Novartis' stock buyback program work?

Novartis announced that its board has approved a share buyback program on Saturday, April 8th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 2.9% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) released its quarterly earnings data on Thursday, April, 19th. The company reported $1.28 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $1.25 by $0.03. The firm earned $12.69 billion during the quarter, compared to the consensus estimate of $12.45 billion. Novartis had a return on equity of 16.23% and a net margin of 16.04%. Novartis's revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.13 earnings per share. View Novartis' Earnings History.

When is Novartis' next earnings date?

Novartis is scheduled to release their next quarterly earnings announcement on Tuesday, July, 17th 2018. View Earnings Estimates for Novartis.

What price target have analysts set for NVS?

10 Wall Street analysts have issued 12 month price objectives for Novartis' stock. Their forecasts range from $82.25 to $91.00. On average, they expect Novartis' stock price to reach $87.75 in the next year. View Analyst Ratings for Novartis.

Who are some of Novartis' key competitors?

Who are Novartis' key executives?

Novartis' management team includes the folowing people:
  • Dr. Vasant Narasimhan, Chief Exec. Officer (Age 42)
  • Mr. Harry Kirsch, Chief Financial Officer (Age 53)
  • Felix R. Ehrat, Group Gen. Counsel (Age 61)
  • Mr. Steven Baert, Head of HR (Age 44)
  • Mr. Richard Francis, CEO, Sandoz (Age 50)

Has Novartis been receiving favorable news coverage?

Press coverage about NVS stock has trended somewhat positive on Friday, Accern Sentiment Analysis reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novartis earned a coverage optimism score of 0.09 on Accern's scale. They also assigned news coverage about the company an impact score of 46.02 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Who are Novartis' major shareholders?

Novartis' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (0.64%), Loomis Sayles & Co. L P (0.34%), Fisher Asset Management LLC (0.30%), Northern Trust Corp (0.18%), Thomaspartners Inc. (0.17%) and BlackRock Inc. (0.17%). Company insiders that own Novartis stock include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Institutional Ownership Trends for Novartis.

Which institutional investors are selling Novartis stock?

NVS stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., The Manufacturers Life Insurance Company , Reynders McVeigh Capital Management LLC, BlackRock Inc., Manning & Napier Group LLC, Federated Investors Inc. PA, Blair William & Co. IL and Senzar Asset Management LLC. View Insider Buying and Selling for Novartis.

Which institutional investors are buying Novartis stock?

NVS stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, Rockefeller Capital Management L.P., Loomis Sayles & Co. L P, Boston Partners, Millennium Management LLC, Point72 Asset Management L.P., Lord Abbett & CO. LLC and Sei Investments Co.. Company insiders that have bought Novartis stock in the last two years include Bioventures Ltd Novartis and Institutes For Biomed Novartis. View Insider Buying and Selling for Novartis.

How do I buy shares of Novartis?

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $76.15.

How big of a company is Novartis?

Novartis has a market capitalization of $177.12 billion and generates $49.11 billion in revenue each year. The company earns $7.70 billion in net income (profit) each year or $4.81 on an earnings per share basis. Novartis employs 121,597 workers across the globe.

How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]


MarketBeat Community Rating for Novartis (NVS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  721
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novartis (NYSE:NVS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
10 Wall Street analysts have issued ratings and price targets for Novartis in the last 12 months. Their average twelve-month price target is $87.75, suggesting that the stock has a possible upside of 15.02%. The high price target for NVS is $91.00 and the low price target for NVS is $82.25. There are currently 2 sell ratings, 7 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.901.801.922.07
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
6 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
6 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $87.75$87.75$84.4050$84.4050
Price Target Upside: 15.02% upside11.08% upside2.85% downside3.26% upside

Novartis (NYSE:NVS) Consensus Price Target History

Price Target History for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/25/2018Credit Suisse GroupUpgradeUnderperform ➝ NeutralLowView Rating Details
5/17/2018JPMorgan Chase & Co.Reiterated RatingNeutralLowView Rating Details
4/20/2018Deutsche BankReiterated RatingNeutralLowView Rating Details
1/15/2018UBSReiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralMediumView Rating Details
12/6/2017Bank of AmericaDowngradeNeutral ➝ UnderperformLowView Rating Details
10/25/2017BarclaysDowngradeEqual Weight ➝ UnderweightN/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$89.00 ➝ $91.00N/AView Rating Details
8/9/2017CowenSet Price TargetHold$90.00MediumView Rating Details
7/26/2017Morgan StanleyUpgradeUnderweight ➝ OverweightLowView Rating Details
3/22/2017Goldman Sachs GroupReiterated RatingNeutralLowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy ➝ BuyLowView Rating Details
3/7/2017Societe GeneraleUpgradeHold ➝ Buy$73.82 ➝ $74.37N/AView Rating Details
3/7/2017BNP ParibasDowngradeNeutral ➝ UnderperformN/AView Rating Details
1/31/2017ArgusUpgradeHold ➝ BuyN/AView Rating Details
1/17/2017Berenberg BankDowngradeBuy ➝ HoldN/AView Rating Details
10/16/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
10/10/2016Chardan CapitalLower Price TargetBuy$95.00 ➝ $92.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Novartis (NYSE:NVS) Earnings History and Estimates Chart

Earnings by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Earnings Estimates

2018 EPS Consensus Estimate: $5.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$1.24$1.31$1.28
Q2 20181$1.34$1.34$1.34
Q3 20181$1.35$1.35$1.35
Q4 20181$1.50$1.50$1.50

Novartis (NYSE NVS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/17/2018        
4/19/2018Q1$1.25$1.28$12.4515 billion$12.6940 billionViewN/AView Earnings Details
1/24/2018n/a$1.16$1.20$12.6464 billion$12.9150 billionViewListenView Earnings Details
10/24/20179/30/2017$1.25$1.29$12.2102 billion$12.4130 billionViewN/AView Earnings Details
7/18/2017Q2 17$1.16$1.22$12.2043 billion$12.2420 billionViewN/AView Earnings Details
4/25/20173/31/2017$1.10$1.13$11.5933 billion$11.5390 billionViewN/AView Earnings Details
1/25/2017Q416$1.12$1.12$12.4407 billion$12.3220 billionViewN/AView Earnings Details
10/25/2016Q316$1.19$1.23$12.24 billion$12.1260 billionViewListenView Earnings Details
7/19/2016Q216$1.18$1.23$12.33 billion$12.47 billionViewListenView Earnings Details
4/21/2016Q116$1.18$1.17$11.90 billion$11.60 billionViewListenView Earnings Details
1/27/2016Q415$1.18$1.14$12.64 billion$12.52 billionViewListenView Earnings Details
10/27/2015Q315$1.31$1.27$12.66 billion$12.30 billionViewListenView Earnings Details
7/21/2015Q215$1.20$1.27$12.45 billion$12.70 billionViewListenView Earnings Details
4/23/2015Q115$1.12$1.33$12.90 million$11.9350 billionViewN/AView Earnings Details
1/27/2015Q314$1.13$1.21$14.68 billion$14.63 billionViewN/AView Earnings Details
10/28/2014Q3 2014$1.29$1.28$14.1420 billion$14.7040 billionViewN/AView Earnings Details
7/17/2014Q214$1.36$1.36$14.8283 billion$14.6370 billionViewN/AView Earnings Details
4/24/2014Q1 2014$1.33$1.31$14.2526 billion$14.0220 billionViewN/AView Earnings Details
1/29/2014Q413$1.27$1.20$15.16 billion$15.0780 billionViewN/AView Earnings Details
10/22/2013Q313$1.31$1.26$14.28 billion$14.34 billionViewN/AView Earnings Details
7/17/2013Q213$1.29$1.30$14.39 billion$14.50 billionViewN/AView Earnings Details
4/24/2013Q113$1.28$1.32$14.02 million$14.0160 billionViewN/AView Earnings Details
1/23/2013Q412$1.19$1.27$14.42 billion$14.80 billionViewN/AView Earnings Details
10/25/2012$1.34$1.34ViewN/AView Earnings Details
7/19/2012$1.33$1.38ViewN/AView Earnings Details
4/24/2012$1.30$1.27ViewN/AView Earnings Details
1/25/2012$1.26$1.23ViewN/AView Earnings Details
10/25/2011$1.45$1.45ViewN/AView Earnings Details
7/19/2011$1.46$1.48ViewN/AView Earnings Details
4/19/2011$1.30$1.41ViewN/AView Earnings Details
1/27/2011$1.25$1.14ViewN/AView Earnings Details
10/21/2010Q3 2010$1.20$1.36ViewN/AView Earnings Details
7/15/2010Q2 2010$1.13$1.20ViewN/AView Earnings Details
1/26/2010Q4 2009$1.16$1.01ViewN/AView Earnings Details
10/22/2009Q3 2009$0.95$0.92ViewN/AView Earnings Details
4/23/2009Q1 2009$0.87$0.87ViewN/AView Earnings Details
1/28/2009Q4 2008$0.79$0.66ViewN/AView Earnings Details
10/20/2008Q3 2008$0.99$0.92ViewN/AView Earnings Details
7/17/2008Q2 2008$0.93$0.99ViewN/AView Earnings Details
1/23/2008Q4 2007$0.67$0.41ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novartis (NYSE:NVS) Dividend Information

Novartis pays an annual dividend of $1.91 per share, with a dividend yield of 2.50%. NVS's most recent annual dividend payment was Friday, March 3. Novartis pays out 39.71% of its earnings out as a dividend.
Most Recent Dividend:3/3/2017
Annual Dividend:$1.91
Dividend Yield:2.50%
Dividend Growth:-0.50% (3 Year Average)
Payout Ratio(s):39.71% (Trailing 12 Months of Earnings)
36.31% (Based on This Year's Estimates)
34.35% (Based on Next Year's Estimates)
25.01% (Based on Cash Flow)
Dividend Payments by Quarter for Novartis (NYSE:NVS)

Novartis (NYSE:NVS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/27/2017Annual$2.32703/1/20173/3/20173/3/2017
2/1/2016Annual$2.342/24/20162/26/20162/26/2016
2/4/2014annual$2.71863.48%2/27/20143/3/20143/11/2014
2/11/2013annual$2.533.71%2/26/20132/28/20134/5/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novartis (NYSE NVS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.01%
Institutional Ownership Percentage: 10.97%
Insider Trading History for Novartis (NYSE:NVS)
Insider Trading History for Novartis (NYSE:NVS)

Novartis (NYSE NVS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2018Institutes For Biomed NovartisMajor ShareholderBuy766,666$15.00$11,499,990.00View SEC Filing  
7/5/2017Bioventures Ltd NovartisMajor ShareholderBuy266,667$15.00$4,000,005.00View SEC Filing  
5/11/2016Institutes For Biomed NovartisMajor ShareholderBuy277,777$18.00$4,999,986.00View SEC Filing  
2/17/2016Bioventures Ltd NovartisMajor ShareholderBuy375,000$8.00$3,000,000.00View SEC Filing  
9/22/2014Bioventures Ltd NovartisMajor ShareholderBuy325,000$15.00$4,875,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Novartis (NYSE NVS) News Headlines

Source:
DateHeadline
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and ...Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and ...
globenewswire.com - May 24 at 8:06 AM
Pharmaceutical companies like Novartis and Lilly are starting to pick up cues from Silicon ValleyPharmaceutical companies like Novartis and Lilly are starting to pick up cues from Silicon Valley
www.businessinsider.com - May 23 at 5:46 PM
Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?Should You Expect Novartis AG (VTX:NOVN) To Continue Delivering An ROE Of 11.33%?
finance.yahoo.com - May 23 at 5:46 PM
Why AveXis chose Durham for its 200-job expansionWhy AveXis chose Durham for its 200-job expansion
finance.yahoo.com - May 23 at 5:46 PM
Company recently acquired by Novartis bringing 200 jobs to DurhamCompany recently acquired by Novartis bringing 200 jobs to Durham
www.bizjournals.com - May 22 at 5:16 PM
[$$] Cohen Probe Trips Up Bridgewater Plan for Board[$$] Cohen Probe Trips Up Bridgewater Plan for Board
finance.yahoo.com - May 22 at 8:09 AM
Cohen Probe Trips Up Bridgewater Plan for BoardCohen Probe Trips Up Bridgewater Plan for Board
www.wsj.com - May 21 at 5:19 PM
Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?Amgen And Novartis Aimovig FDA Approval Gives First Mover Advantage, Will That Be Enough?
seekingalpha.com - May 21 at 8:05 AM
The FDA Approved a Promising New Drug to Treat Migraines. Now, the Drugmakers Stock Prices Are RisingThe FDA Approved a Promising New Drug to Treat Migraines. Now, the Drugmakers' Stock Prices Are Rising
fortune.com - May 19 at 6:03 PM
Amgen, Novartis Clinch FDA Nod on Migraine Prevention DrugAmgen, Novartis Clinch FDA Nod on Migraine Prevention Drug
www.thestreet.com - May 19 at 8:02 AM
CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYICBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI
finance.yahoo.com - May 19 at 8:02 AM
How Michael Cohen Became a $1.2 Million Headache for NovartisHow Michael Cohen Became a $1.2 Million Headache for Novartis
www.bloomberg.com - May 18 at 6:16 PM
Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analystMigraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
finance.yahoo.com - May 18 at 6:16 PM
After hullabaloo, Greek lawmakers drop Novartis probe against ex ministersAfter hullabaloo, Greek lawmakers drop Novartis probe against ex ministers
finance.yahoo.com - May 18 at 6:16 PM
Benzingas Daily Biotech Pulse: AstraZenecas Q1, Novartis-Amgen Migraine Drug ApprovedBenzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved
feeds.benzinga.com - May 18 at 8:31 AM
BRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine PreventionBRIEF-Novartis, Amgen Announce FDA Approval Of Aimovig Treatment For Migraine Prevention
www.reuters.com - May 18 at 8:11 AM
FDA approves anti-migraine drug from Novartis, AmgenFDA approves anti-migraine drug from Novartis, Amgen
www.marketwatch.com - May 18 at 8:11 AM
Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
finance.yahoo.com - May 18 at 8:11 AM
Top Novartis Lawyer Resigns Over Michael Cohen DealTop Novartis Lawyer Resigns Over Michael Cohen Deal
www.huffingtonpost.com - May 17 at 7:14 PM
Trump Lawyer Cohen Dangled Policy Help, Ex-Novartis Chief SaysTrump Lawyer Cohen Dangled Policy Help, Ex-Novartis Chief Says
www.bloomberg.com - May 17 at 7:14 PM
FDA names drugmakers accused of blocking cheaper genericsFDA names drugmakers accused of blocking cheaper generics
finance.yahoo.com - May 17 at 7:14 PM
JPMorgan Chase Reaffirms Neutral Rating for Novartis (NVS)JPMorgan Chase Reaffirms Neutral Rating for Novartis (NVS)
www.americanbankingnews.com - May 17 at 11:35 AM
Novartis: Buy Under $80Novartis: Buy Under $80
seekingalpha.com - May 17 at 8:07 AM
Novartis Top Lawyer Departs Over Cohen PaymentsNovartis Top Lawyer Departs Over Cohen Payments
www.wsj.com - May 17 at 8:07 AM
[$$] Novartis Top Lawyer Departs Over Cohen Payments[$$] Novartis Top Lawyer Departs Over Cohen Payments
finance.yahoo.com - May 17 at 8:07 AM
[$$] The Novartis-Cohen Connection Explained[$$] The Novartis-Cohen Connection Explained
finance.yahoo.com - May 17 at 8:07 AM
Novartis (NVS) Expected to Announce Earnings of $1.31 Per ShareNovartis (NVS) Expected to Announce Earnings of $1.31 Per Share
www.americanbankingnews.com - May 16 at 7:12 PM
Novartis Lawyer to Step Down After Cohen PaymentsNovartis Lawyer to Step Down After Cohen Payments
www.bloomberg.com - May 16 at 5:58 PM
Former Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 MillionFormer Novartis CEO Explains Why His Company Paid Trump Lawyer Michael Cohen $1.2 Million
www.forbes.com - May 16 at 5:58 PM
How Trumps Fix-It Man Became a $1.2 Million Headache for NovartisHow Trump's Fix-It Man Became a $1.2 Million Headache for Novartis
finance.yahoo.com - May 16 at 5:58 PM
Novartis General Counsel Out Over Cohen ContractNovartis General Counsel Out Over Cohen Contract
finance.yahoo.com - May 16 at 5:58 PM
Here’s how Novartis’s former CEO explained hiring Michael CohenHere’s how Novartis’s former CEO explained hiring Michael Cohen
finance.yahoo.com - May 16 at 5:58 PM
Novartis general counsel to step down after payments to Trumps lawyerNovartis general counsel to step down after payments to Trump's lawyer
www.latimes.com - May 16 at 8:49 AM
BRIEF-Novartis CEO "Looking Hard" At US Solid Generics Business At SandozBRIEF-Novartis CEO "Looking Hard" At US Solid Generics Business At Sandoz
www.reuters.com - May 16 at 8:03 AM
Air France-KLM, Novartis and Cohen, Soros and Tesla: CEO Daily for May 16, 2018Air France-KLM, Novartis and Cohen, Soros and Tesla: CEO Daily for May 16, 2018
fortune.com - May 16 at 8:03 AM
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive ...At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive ...
globenewswire.com - May 16 at 8:03 AM
Novartis ex-CEO says regrets hiring, not firing Trump lawyerNovartis ex-CEO says regrets hiring, not firing Trump lawyer
finance.yahoo.com - May 16 at 8:03 AM
Top lawyer at Novartis exits in wake of deal with Trump attorney Michael CohenTop lawyer at Novartis exits in wake of deal with Trump attorney Michael Cohen
www.cnbc.com - May 16 at 6:15 AM
Novartis CEO Dials Up 5000 Managers After Cohen FurorNovartis CEO Dials Up 5000 Managers After Cohen Furor
www.bloomberg.com - May 15 at 5:58 PM
Novartis successfully completes acquisition of AveXis, Inc.Novartis successfully completes acquisition of AveXis, Inc.
finance.yahoo.com - May 15 at 5:58 PM
Novartis To Initiate Proof Of Concept Study With Cosentyx - Quick FactsNovartis To Initiate Proof Of Concept Study With Cosentyx - Quick Facts
www.nasdaq.com - May 15 at 8:10 AM
Democrats demand answers from AT&T and Novartis about payments to Trumps lawyerDemocrats demand answers from AT&T and Novartis about payments to Trump's lawyer
www.cnbc.com - May 15 at 8:10 AM
Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition ...Novartis ARROW trial to assess mechanistic superiority of direct IL-17A inhibition (Cosentyx®) over IL-23 inhibition ...
globenewswire.com - May 15 at 8:10 AM
Democrats demand answers from AT&T and Novartis about pay...Democrats demand answers from AT&T and Novartis about pay...
finance.yahoo.com - May 15 at 8:10 AM
Swiss prosecutors eye Novartiss deal with Cohen: reportsSwiss prosecutors eye Novartis's deal with Cohen: reports
finance.yahoo.com - May 15 at 8:10 AM
Novartis completes tender offer for all outstanding shares of AveXis, Inc.Novartis completes tender offer for all outstanding shares of AveXis, Inc.
finance.yahoo.com - May 15 at 8:10 AM
Novartis Multiple Sclerosis Drug Gets FDA Nod for AdolescentsNovartis Multiple Sclerosis Drug Gets FDA Nod for Adolescents
www.zacks.com - May 14 at 5:30 PM
Novartiss Cohen Payment Is Subject of Swiss Prosecutor TalksNovartis's Cohen Payment Is Subject of Swiss Prosecutor Talks
www.bloomberg.com - May 14 at 5:30 PM
Democratic senators demand answers from AT&T and Novartis about payments to Trump lawyer Cohens companyDemocratic senators demand answers from AT&T and Novartis about payments to Trump lawyer Cohen's company
www.cnbc.com - May 14 at 4:28 PM
Novartiss Gilenya gets FDA pediatric approvalNovartis's Gilenya gets FDA pediatric approval
www.marketwatch.com - May 14 at 8:09 AM

SEC Filings

Novartis (NYSE:NVS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novartis (NYSE:NVS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novartis (NYSE NVS) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.